Asia-Pacific journal of clinical oncology最新文献

{"title":"Ferroptosis: A Mechanism of Cell Death With Potential Scope in Cancer Therapy","authors":"Mukherjee Bipasha,&nbsp;Vidhate Deepali,&nbsp;Deb Prabal,&nbsp;Khillare Supriya,&nbsp;Bangar Megha","doi":"10.1111/ajco.14172","DOIUrl":"10.1111/ajco.14172","url":null,"abstract":"<p>Ferroptosis is a type of regulated cell death caused by oxidative imbalance of the intracellular microenvironment. This causes the accumulation of toxic lipid peroxides, depicted by iron overload and lipid peroxidation, which results in disease development. The affected cell population displays unique morphological and biochemical features, which are distinct from other modes of cell death, like apoptosis, pyroptosis, and necroptosis. The individual pathways of each of these modes are interrelated and tend to counterbalance each other in the mechanism of cell death. The process of ferroptosis is associated with disturbances in iron metabolism, in conjunction with glutathione peroxidase and lipid peroxidation, culminating in a reduction of antioxidant capacity and accumulation of lipid peroxides in the dying cell. It has been observed that even excess cellular levels of iron can cause cell death, where ferroptosis is initiated by diminishing the levels of glutathione and glutathione peroxidase 4, and thus leading to excess build-up of lipid reactive oxygen species (ROS). In the case of a neoplastic cell, ferroptosis along with its regulators tends to orchestrate cell death and also affects cancer progression by modulation of proliferation activity, apoptosis suppression, metastasis, and drug resistance. Comprehending the complex network of molecular processes implicated in ferroptosis regulation is vital for developing targeted therapies for diseases where ferroptosis plays a significant role.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 5","pages":"465-473"},"PeriodicalIF":1.6,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14172","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Ultrasound be Used as an Alternative Tool for Pancreatic Cystic Disease Compared With MRI?","authors":"Lu-ying Gao,&nbsp;Jiang Ji,&nbsp;Yu Xia,&nbsp;Ya Hu,&nbsp;Liyuan Ma,&nbsp;Aonan Pan,&nbsp;Yuang An,&nbsp;Nengwen Luo,&nbsp;Yuxin Jiang","doi":"10.1111/ajco.14170","DOIUrl":"10.1111/ajco.14170","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Rationale and Objectives</h3>\u0000 \u0000 <p>To analyze the ultrasound features of pancreatic cystic lesions and to compare contrast-enhanced sonography (CEUS) with magnetic resonance imaging (MRI) to investigate the diagnostic value of CEUS for pancreatic cystic lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Patients with pancreatic cystic lesions who underwent CEUS examination and enhanced MRI from February 2022 to January 2023 at Peking Union Medical College Hospital were prospectively included. The diagnostic value of CEUS in the diagnosis of pancreatic cystic lesions was analyzed using postoperative histopathology as the gold standard and compared with enhanced MRI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 17 patients with pancreatic cystic lesions were included, the CEUS diagnostic accuracy was 76.47% (13/17), the enhanced MRI diagnostic accuracy was 64.71% (11/17), and the diagnostic results of CEUS were in moderate agreement with those of enhanced MRI (<i>κ</i> = 0.52). The CEUS features of all lesions were categorized into four types: Type I, unilocular cystic type, five cases; Type II, microcystic lesion type, four cases; Type III, macrocystic lesion type, two cases; and Type IV, lesion with an enhanced solid component, six cases. There were two cases of Type I and one case of Type II simple cysts. Pancreatic pseudocysts were Type I in one case. Of the pancreatic serous cystadenomas, three cases were Type II, two cases were Type III, and one case was Type IV. The case of pancreatic mucinous cystadenoma was Type I. For the intraductal papillary mucinous neoplasm, four cases were all Type IV. For solid pseudopapillary tumors of the pancreas, one case was classified as Type IV. One case of pancreatic neuroendocrine tumor was classified as Type I.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>CEUS, as an economical, radiation-free, and effective imaging modality, can be an optional test for pancreatic cystic diseases and helps in their diagnosis and follow-up.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"439-444"},"PeriodicalIF":1.4,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Pleural Mesothelioma Management: Integrating Radiomics, AI, and Predictive Models for Improved Patient Outcomes","authors":"Muzamil Akhtar,&nbsp;Hanzala Ahmed Farooqi,&nbsp;Rayyan Nabi,&nbsp;Zenia Safwan","doi":"10.1111/ajco.14169","DOIUrl":"10.1111/ajco.14169","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"449-450"},"PeriodicalIF":1.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Optimal Timing and Duration of Daily G-CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy","authors":"Zisun Kim,&nbsp;Sung Mo Hur,&nbsp;Jong Eun Lee,&nbsp;Sun Wook Han,&nbsp;Hae Il Jung,&nbsp;Sung Yong Kim,&nbsp;Jihyoun Lee,&nbsp;Cheol Wan Lim","doi":"10.1111/ajco.14165","DOIUrl":"10.1111/ajco.14165","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>TAC chemotherapy is a standard adjuvant treatment for early-stage breast cancer, with G-CSF recommended for preventing febrile neutropenia (FN). This study investigates the optimal initiation timing for daily filgrastim to prevent FN in patients undergoing TAC chemotherapy, a subject not fully explored in existing guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty breast cancer patients receiving adjuvant TAC chemotherapy were randomly assigned to start daily filgrastim either on Day 2 (Day 2 group, <i>n</i> = 30) or Day 5 (Day 5 group, <i>n</i> = 30). The primary outcome was the incidence of FN. Secondary outcomes included the duration of neutropenia treatment and the neutropenia profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients underwent 349 cycles of TAC chemotherapy (173 cycles in Day 2 group and 176 cycles in Day 5 group). The incidence of FN was significantly lower in the Day 2 group (6.4%, 11/173) compared to the Day 5 group (22.2%, 39/176, <i>p</i> &lt; 0.0001). Additionally, the mean ± SD duration of filgrastim treatment was longer (8 ± 1 vs. 6 ± 1 days, <i>p</i> &lt; 0.0001), and the duration of severe neutropenia was shorter (3 ± 1 vs. 4 ± 1 days, <i>p</i> = 0.001) in the Day 2 group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Initiating filgrastim on Day 2 of TAC chemotherapy significantly enhances its effectiveness in preventing FN compared to starting on Day 5. These findings support early intervention and sustained treatment to optimize toxicity management in adjuvant TAC chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"383-391"},"PeriodicalIF":1.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14165","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience Using Brigimadlin (MDM2 Inhibitor) in an Australian Sarcoma Specialist Center Compared to Pivotal Clinical Trial Results","authors":"Karan Gupta,&nbsp;Peter Grimison","doi":"10.1111/ajco.14168","DOIUrl":"10.1111/ajco.14168","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"447-448"},"PeriodicalIF":1.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Artificial Intelligence in NAFLD Diagnosis: A New Frontier in Managing Metastatic Prostate Cancer Risk”","authors":"Zenia Safwan,&nbsp;Hanzala Ahmed Farooqi,&nbsp;Rayyan Nabi","doi":"10.1111/ajco.14167","DOIUrl":"10.1111/ajco.14167","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"451-452"},"PeriodicalIF":1.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"E2F4 Promotes Malignant Behaviors of Prostate Cancer Through Activating MUC1 Expression Transcriptionally","authors":"Long Cheng,&nbsp;Haichao Yang,&nbsp;Shuoguo Tan,&nbsp;Chongjun Shi,&nbsp;Fanfei Zeng,&nbsp;Weizhong Yang,&nbsp;Weiqin Kong","doi":"10.1111/ajco.14164","DOIUrl":"10.1111/ajco.14164","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The malignant features of prostate cancer (PC) threaten the patient's life. MUC1 was observably enhanced in PC. However, the reason for higher MUC1 expression in PC is still unclear and deserves to be further investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The abundance of MUC1 and E2F4 was evaluated using RT-qPCR in PC patients and PC cells. Pearson correlation coefficient analyzed the relationship between E2F4 and MUC1 in tissues from PC patients. Malignant phenotypes were examined using clone formation, scratch tests, transwell, and flow cytometry. The JASPAR website, luciferase activity assay, and ChIP were employed for validating interplays between E2F4 and the MUC1 promoter.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MUC1 and E2F4 were abnormally elevated in samples of PC patients and PC cells. MUC1 silencing resulted in suppression of growth and metastasis and promotion of cell apoptosis of PC cells. Additionally, E2F4 could provoke the transcriptional activity of MUC1 to enhance MUC1 expression. Furthermore, E2F4 knockdown inhibited malignant features of PC cells, which was abolished by MUC1 overexpression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings revealed that E2F4 silencing led to the suppression of growth and metastasis and the promotion of cell apoptosis of PC cells through reducing MUC1 expression, which offered targeting molecules for PC treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 5","pages":"557-565"},"PeriodicalIF":1.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14164","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Chemotherapy With Chemoradiotherapy for Patients With Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma—Retrospective Review From a Tertiary Care Hospital","authors":"Avtaj Nerwal,&nbsp;Desmond Yip,&nbsp;Sivakumar Gananadha,&nbsp;Amy Shorthouse,&nbsp;Belinda Lee,&nbsp;Ankit Jain","doi":"10.1111/ajco.14166","DOIUrl":"10.1111/ajco.14166","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Patients diagnosed with borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) have historically worse survival rates compared to those with resectable pancreatic cancer. The study aimed to assess the feasibility and efficacy of neoadjuvant chemotherapy and chemoradiotherapy in BRPC/LAPC. Additionally, we evaluated the R0 resection rates for patients who progressed to surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included patients diagnosed with BRPC/LAPC between January 2019 and December 2023 at The Canberra Hospital (TCH), a tertiary care setting. A total of 115 patients were screened, of whom 37 were eligible for inclusion. Demographic data, CA19-9 levels, treatment regimens, surgical outcomes, resection rates, disease-free survival (DFS), and overall survival were analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 20 (54%) patients (15 FOLFIRINOX and 5 gemcitabine/nab-paclitaxel) completed their planned chemotherapy, and 17 (46%) of these patients had chemoradiotherapy, majority receiving 45–50 Gy of conventional radiation with capecitabine. Tumor marker Ca19-9 normalized after chemotherapy in seven patients (19%). In total, 23 patients (62.2%) progressed to surgery. The median DFS for all patients was 12.7 months (95% CI 5.5–15.9), and the median OS was 21 months (95% CI 13.7–44.9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study suggests that neoadjuvant treatment is feasible for BRPC/LAPC, allowing patients to undergo surgery and achieve R0 resection. However, further randomized controlled trials with larger cohorts are needed to validate these findings and refine treatment protocols.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"392-398"},"PeriodicalIF":1.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical Activity and Its Barriers During the First Year Following Breast Cancer Surgery","authors":"Namo Jeon,&nbsp;Si-Woon Park,&nbsp;Doo Young Kim,&nbsp;Hyeong-Wook Han,&nbsp;Bum-Suk Lee,&nbsp;Ilkyun Lee","doi":"10.1111/ajco.14163","DOIUrl":"10.1111/ajco.14163","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Physical activity and body fatness affect breast cancer development and outcome. There is a tendency to reduce physical activity in the early stages of breast cancer treatment, but exercise interventions are rarely implemented during this period.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This study aimed to longitudinally assess the physical activity in patients with breast cancer during the first year after surgery and to investigate the factors associated with inactivity.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A retrospective cohort study.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A university hospital.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We reviewed the medical records of patients with breast cancer who visited the cancer rehabilitation clinic more than once.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Interventions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Not applicable.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Physical activity was assessed using the International Physical Activity Questionnaire. Body fatness was evaluated by calculating body mass index and body fat proportion obtained using bioimpedance. The physical function and health-related quality of life (HRQoL) were also assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 130 patients were included. At initial evaluation, the total amount of physical activity was 1942.8 ± 2977.4 METs, with 46 (35.4%) participants categorized as inactive. The number of overweight/obese participants was 81 (62.3%), and 45 individuals had a high fat proportion (&gt;35.0%). At follow-up, there were no statistically significant changes in all parameters. However, the total amount of physical activity was increased to 2045.2 ± 2561.1 METs, and the number of inactive participants was reduced to 35 (26.2%) without statistical significance. Additionally, the number of overweight/obese participants was reduced to 76 (58.5%), and the number of participants with a high fat proportion was reduced to 35 (26.9%), without statistical significance. Physical function and HRQoL did not significantly change. The factors associated with inactivity included leg strength, chemotherapy at baseline, and body fat proportion at follow-up.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"433-438"},"PeriodicalIF":1.4,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Availability and Characteristics of Support Groups for People With Head and Neck Cancer in Australia","authors":"Ashleigh R. Sharman,&nbsp;Yuan Peng,&nbsp;Rebecca L. Venchiarutti","doi":"10.1111/ajco.14158","DOIUrl":"10.1111/ajco.14158","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Support groups are an effective way to improve quality of life (QoL) in cancer patients. Targeted support groups for head and neck cancer (HNC) can also help patients address specific treatment and survivorship challenges. The aim of this study is to understand the characteristics of existing HNC support groups in the Australian setting and identify any gaps in service provision.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Existing HNC support groups were identified through an online search and their online information was assessed by adopting the perspective of a person with HNC. Support groups were considered eligible for this study if they were based in Australia and served HNC patients, their caregivers, friends, or family members.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 26 support groups identified in the online search, more than half were based in major cities (<i>n</i> = 16) with three support groups across inner regional areas and three across outer regional areas. There were no support groups identified in remote areas of Australia. Most support groups took place in-person (<i>n</i> = 18) across a variety of physical settings, including hospitals (<i>n</i> = 10) and community spaces (<i>n</i> = 7). Topics frequently covered included: Education and information, sharing experiences and socializing, treatment and side effects, wellness and well-being, and carer support.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There is a need for HNC support groups outside of metropolitan areas, particularly in remote Australia. We must therefore identify means of supporting current and future groups in providing and promoting their valuable service to HNC patients across all locales.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 4","pages":"415-424"},"PeriodicalIF":1.4,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}